Three Big Questions at HLTH 2024

In just a few days, leaders and innovators from across the world of healthcare and technology will gather in Las Vegas for this year’s HLTH conference. Our Real Chemistry Digital Health team will be there, and we’ve been thinking a lot about the big questions that we know will be driving conversations on and around the show floor.

How is AI impacting – and improving – healthcare?

Over the past few years, it’s been impossible to avoid conversations about the rapid and impressive growth of AI tools. From smart assistants that simplify record keeping for providers to advanced generative AI designed to identify potential new molecules for treating rare and severe diseases, the potential use-cases for AI have run the gamut. At this year’s HLTH though, we’re expecting to see conversations not just about the potential of AI, but of the real and tangible impact that AI is having in health today for providers, payers, pharmaceutical innovators and, of course, patients. We know that to see broad adoption of AI in healthcare, stakeholders across the ecosystem want to see how it positively impacts better patient outcomes from the industry’s AI pioneers.

Where is technology making healthcare easier to use and access – and where is there still room for improvement?

When healthcare services are readily available and pleasant to use, more people take advantage of them and outcomes improve. We expect that we’ll see no shortage of ambitious startups and long-standing industry players showcasing the ways that they’re innovating to center patients and improve the care experience at HLTH. But what we hope to also see is conversations about where problems remain and how the industry plans to address them. We asked Verily, an Alphabet health technology company focused on research, care, and public health, about the topics they are looking forward to at the conference.

“I'm looking forward to hearing about new solutions and opportunities to addressing inequities in care delivery, chronic care management, as well as the role of technology and data in helping communities better monitor the spread of disease." -Caela Shay, Senior Director, Communications, Verily

Just how big is the impact of GLP-1 medications?

With some influencers calling GLP-1 agonists “the biggest thing since penicillin,” it’s no shock that the HLTH agenda is full of conversations about the broader impact of these drugs on the health care landscape. From discussions around the impact of their high costs on payers, to the equity implications around access, to the way their prominence may affect other aspects of cardiometabolic care, there’s no shortage of reasons to talk about these medications. Noom, a digital healthcare company focused on innovation and whole-person health, will be helping to shape conversation on GLP-1s at HTLTH:

“We are looking forward to conversation about how our industry can better address access and affordability of weight loss medications to solve the current crisis we face, as overwhelming demand has quickly outpaced supply. We believe pharma manufacturers and companies commercializing compounded GLP-1s must unite to find solutions for patients, and HLTH will be the perfect setting for those discussions.” - Brandyn Bissinger, Head of Global Communications, Noom

We’re at a critical moment in healthcare and these are just some of the important conversations around the future of how we deliver care and create a healthier world. We’re excited to attend HLTH 2024 to make new connections, showcase the work we’ve been doing and learn from the leaders driving the future of health.?